Trial Profile
DIVERGE-II
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2010
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms DIVERGE-II
- Sponsors Devax
- 08 Jun 2009 New trial record.
- 30 May 2009 The U.S. Food and Drug Administration has conditionally approved an Investigational Device Exemption the AXXESS Biolimus A9-eluting stent, allowing the company to initiate this pivotal trial in the USA; as reported by Devax in a media release